Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
Advanced search 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 446 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

ORIGINAL ARTICLE Table of Contents   
Year : 2003  |  Volume : 14  |  Issue : 2  |  Page : 158-164
The Use of Alphacalcidol Intravenously in Hemodialysis Patients: Experience from Bahrain

1 Consultant Nephrologist, Salmaniya Medical Complex, Bahrain
2 Chief Resident, Salmaniya Medical Complex, Bahrain
3 Consultant in Biochemistry, Salmaniya Medical Complex, Bahrain
4 Technologist in Biochemistry, Salmaniya Medical Complex, Bahrain

Correspondence Address:
Sameer Al-Arrayed
Department of Nephrology, Salmaniya Medical Complex, P.O. Box 12, Manama
Login to access the Email id

PMID: 18209441

Rights and Permissions

While the effects of vitamin D, one-alphahydroxycholecalciferol (alphacalcidol) administered intravenously on the serum levels of parathormone (PTH) and calcium in dialysis patients have been well studied in the past few years, no detailed studies were conducted in patients from this part of the world. We studied nine patients (four men and five women) who received this drug for 12 weeks. The mean age of the patients was 54.4 19.8 (range: 23-81) years and the duration on dialysis was 40.1 15.6 (range: 18-62) months. The patients were selected on the basis of baseline serum intact PTH values of more than twice the upper limit of normal; all of the patients were on oral alphacalcidol, which was stopped before the study. Alphacalcidol was administered during the last fifteen minutes of each dialysis session, three times per week. The dose of the drug was upregulated weekly to a maximum of 6g per session according to the degree of suppression of PTH and/or the development of hypercalcemia. The results showed a significant decrease of the mean serum PTH from baseline of 77.58 49.13 to 41.87 48.87 pmol/L (p<0.02). Serum phosphate 2.01 0.27 and calcium 2.38 0.25 did not change significantly from baseline . None of the patients developed local or systemic adverse reaction to the injection; only one patient developed hypercalcemia requiring short interruption of the vitamin D with later resumption at a lower dose. In conclusion, alphacalcidol administered intravenously is effective and safe in hemodialysis patients.

Print this article  Email this article

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded263    
    Comments [Add]    

Recommend this journal